Firm Novo Nordisk’s global patent is set to expire in parts of the world from early 2026, allowing cut-price ‘own-label’ versions of Wegovy and Ozempic to be sold, according to reports
New drugmakers could soon offer ‘£20-a-month’ Ozempic-style weight-loss jabs … from the Independent Tara Cobham
